Phaseout of chlorofluorocarbons (CFCs) in metered-dose inhalers. Highlights of the Canadian initial transition strategy.
(1999)
Journal - Canadian family physician Médecin de famille canadien (CANADA )
| ISSN : | 0008-350X |
|---|
| Mesh Heading : | Air Pollution Asthma Canada Chlorofluorocarbons Humans Lung Diseases, Obstructive Nebulizers and Vaporizers drug therapy adverse effects drug therapy |
|---|
| Mesh Heading Relevant : | Public Policy prevention & control standards standards |
|---|
Long-acting beta 2-agonists. Role in primary care asthma treatment.
(1997)
Journal - Canadian family physician Médecin de famille canadien (CANADA )
Abstract :
OBJECTIVE: To examine the efficacy of long-acting beta 2-agonists and their role in primary care asthma management and to review briefly the pharmacology of these agents. QUALITY OF EVIDENCE: Most data presented were derived from randomized, double-blind, placebo-controlled trials. Studies were selected for relevance to asthma management in primary care. MAIN FINDINGS: Long-acting beta 2-agonist use is associated with improvements in both objective and subjective measures of asthma control. At present no evidence suggests that long-acting beta 2-agonists have anti-inflammatory potential. While salmeterol has a longer duration of action than short-acting beta 2-agonists, its onset of action is slower. Salmeterol and formoterol, therefore, should not be used for relief of acute bronchospasm. CONCLUSION: Long-acting beta 2-agonists could be useful for treating asthma in primary care, particularly for controlling symptoms of nocturnal asthma and exercise-induced asthma and for providing convenient maintenance therapy for patients who require regular use of short-acting beta 2-agonists despite concomitant use of optimal doses of inhaled anti-inflammatory medication.
| ISSN : | 0008-350X |
|---|
| Mesh Heading : | Adrenergic beta-Agonists Albuterol Asthma Bronchodilator Agents Child Ethanolamines Humans pharmacology pharmacology therapeutic use pharmacology pharmacology |
|---|
| Mesh Heading Relevant : | therapeutic use analogs & derivatives drug therapy therapeutic use therapeutic use |
|---|